Pluvicto® now publicly funded in provinces covering most Canadians, offering renewed hope to those facing progressive PSMA-positive metastatic ...

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) is among the best growth stocks to invest in for the next 5 years. During the ...

Lantheus Holdings offers a compelling bull case, with PYLARIFY and DEFINITY driving valuation and strong growth prospects.

The global Radioligand Therapy (RLT) market is poised to reach US$13 billion by 2030, expanding at a ~5% CAGR over the ...

The "Nuclear Medicine Market Size, Share & Trends Analysis Report by Product (Diagnostics, Therapeutics), Application ...

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

June brought major prostate cancer updates, and CURE is sharing the latest FDA approvals, label expansions, and emerging data ...

Financial giant UBS has declared that enough is enough with lagging healthcare valuations – and now believes it will be the ...

Pluvicto meanwhile brought in $980 million in 2023, and Novartis is modelling peak sales above $2 billion if it expands into earlier lines of therapy in PSMA-positive metastatic castration ...

While the Australian market is relatively well-positioned, it is vulnerable to broader market shocks, says SG Hiscock & ...

Significant progress in this field is evident with the FDA and EMA approval of two groundbreaking treatments: Lutathera for gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and Pluvicto ...